Drug Development TechnologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9

406 records returned

Almac Doubles Capacity at North Carolina FacilityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Almac group has completed a 67,000ft² expansion to their North Carolina facility in Durham, which now houses both the Clinical Services and Diagnostics divisions. Almac Clinical Services first began occupancy of the additional building on the campus in February 2008 and have since added a 30,000ft² warehouse complete with two new loading docks. Staff from Almac Diagnostics' nearby facility in Durham have relocated to the site and are engaged in research activity across a wide-range of projects. This expansion has greatly increased storage capacity for clinical supplies with a... (Source: Drug Development Technology)
Source: Drug Development Technology - November 20, 2009 Category: Pharmaceuticals Source Type: info

Bachem Releases New Building Blocks and Immunology ProductsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include the novel biomarker copeptin, 6-Azido-hexanoic acid for 'click chemistry' and several other building blocks, the non-ionic detergent MEGA-12, and a range of new immunology products. Today's release of 16 new products includes: Copeptin Copeptin is an inactive fragment of the vasopressin precursor. As a biomarker it serves as a novel predictor of outcome in heart failure. Copeptin (human) Copeptin (rat) Pe... (Source: Drug Development Technology)
Source: Drug Development Technology - November 19, 2009 Category: Pharmaceuticals Source Type: info

ARTES and Rhein Minapharm Continue Their Successful Product Development CollaborationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ARTES Biotechnology, specialised in recombinant protein production and process development from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE, jointly announced the successful production of a new target of a therapeutic protein. This was the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009. ARTES applied its proprietary Hansenula technology platform to this research collaboration and it also applied its know-how to the generation of a therape... (Source: Drug Development Technology)
Source: Drug Development Technology - November 17, 2009 Category: Pharmaceuticals Source Type: info

Sygnature Chemical Services and RespiVert Provide Update on Successful Discovery CollaborationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sygnature Chemical Services, a leading provider of medicinal and computational chemistry services to the global pharmaceutical industry, and RespiVert, a small molecule drug discovery company developing improved treatments for patients with severe respiratory disease, today provided an update on their research collaboration, first announced in January 2008. Under the terms of the agreement Sygnature have provided a comprehensive medicinal chemistry discovery platform for two of RespiVert's leading programmes aimed at identifying novel therapeutic agents for the treatment of poorly controlle... (Source: Drug Development Technology)
Source: Drug Development Technology - November 17, 2009 Category: Pharmaceuticals Source Type: info

Animascope to Present its R&D Imaging Services at BIOTECH 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Animascope recently attended the BIO-Europe 2009 partnering event, which was held in Vienna, Austria, and the company now plans to attend the BIOTECH 2009 biotechnology fair, which will take place 25-27 November in Milano, Italy. Animascope is dedicated to providing non-invasive biomedical imaging services, and regularly attends industry events in order to increase its presence in the sector and stay up to date with the latest developments in the biotechnology and biopharmaceutical fields. Animascope invites you to join them at BIOTECH 2009, where you will be able to find out more about ... (Source: Drug Development Technology)
Source: Drug Development Technology - November 16, 2009 Category: Pharmaceuticals Source Type: info

Qlucore Expands its Marketing Efforts with New High-Profile Appointment to BoardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Qlucore, a world leader in the development of bioinformatics software, has appointed Pia Gideon, the former vice-president of marketing and communication at Ericsson, to its board of directors. "Qlucore is now ready for the next phase of expansion, and we are thrilled to have Pia Gideon joining us, as we know that Qlucore will benefit from her extensive experience in global marketing and communications," says Cecilia Schelin Seidegård, chairman of the board. Qlucore is best known for its highly intuitive Qlucore Omics Explorer product, which enables instant analysis and adds i... (Source: Drug Development Technology)
Source: Drug Development Technology - November 13, 2009 Category: Pharmaceuticals Source Type: info

ETS Releases Free Whitepaper: Effects of an Ultraviolet B Radiation Absorber on Photocarcinogenesis in Hairless Albino MiceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Henk Tennekes, manager of ETS Nederland, has been involved in a recent study that explored the effects of an ultraviolet B radiation absorber on photocarcinogenesis in hairless albino mice. To find out more about the aims, methods and results of the study click here to download the free whitepaper.... (Source: Drug Development Technology)
Source: Drug Development Technology - November 11, 2009 Category: Pharmaceuticals Source Type: info

An FDA Expert on Protecting Yourself Against the FDAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cerulean's co-founder and managing director, John Avellanet, will reprise his talk from September this coming December in an encore presentation of 'Bulletproof Yourself against FDA Enforcement in 2010'. "I received at least half a dozen emails from folks who wanted to attend another live event," said Mr Avellanet. "This is probably the most popular webinar and teleconference I give – it fills up every single time." In ninety minutes Mr Avellanet covers the FDA's directions and priorities for the following year, how firms can identify and mitigate their specific challenges when it comes ... (Source: Drug Development Technology)
Source: Drug Development Technology - November 3, 2009 Category: Pharmaceuticals Source Type: info

Meet Biovian at BioEurope 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Meet Biovian at the BioEurope 2009 partnering conference, which will be held 2-4 November 2009 in Vienna, Austria. Biovian's director of projects and marketing, Dr Knut Ringbom, will be available for the one-to-one partnering offered at the conference. To request a meeting please sign up at the BioEurope conference partnering website. ... (Source: Drug Development Technology)
Source: Drug Development Technology - October 27, 2009 Category: Pharmaceuticals Source Type: info

Animascope to Attend BIO-Europe 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Animascope is dedicated to providing non-invasive biomedical imaging services, and regularly attends industry events in order to increase its presence in the sector and stay up to date with the latest developments in drug development technology. Animascope recently attended the MipTec 2009 fair, which was held in Basel, Switzerland, and the company now plans to attend the BIO-Europe 2009 biotechnology conference, which will take place 2-4 November in Vienna, Austria. Animascope will participate in the partnering event. Animascope invites you to join them at BIO-Europe 2009, where you wil... (Source: Drug Development Technology)
Source: Drug Development Technology - October 23, 2009 Category: Pharmaceuticals Source Type: info

The Latest News from FOCUS Clinical Drug DevelopmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We would like to inform our sponsors about our new capabilities and latest accomplishments: The recent FDA pre-approval inspection audit of our Phase II clinical study site and office facilities in Moscow, Russia, was flawless and resulted in no FDA 483 remarks for the sponsor Our biomarker facility in Heidelberg, Germany, was GLP qualified in February 2009 Several first-in-human studies with biologicals have been performed in our hospital-based ward in Düsseldorf, Germany, which has just been upgraded from six to 12 beds Our expertise in the conduct of ethnic bridging studies... (Source: Drug Development Technology)
Source: Drug Development Technology - October 20, 2009 Category: Pharmaceuticals Source Type: info

Nanoxis to Attend 3rd Annual Proteomics Europe Conference and ExhibitionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nanoxis will attend the 3rd Annual Proteomics Europe conference and exhibition in Barcelona, which will be held 5-6 November 2009. This conference and exhibition is co-located with Advances in Metabolic Profiling, Mass Spec Europe and the European Biomarkers Summit. For more information on LPI™ technology and its applications, please visit Dr Anders Karlsson at the exhibition at booth 11. On Friday 6 November at 3pm Dr Karlsson will also give a talk entitled 'Immobilized native membrane proteins - probing solvent exposed domains through enzymatic digestion'. ... (Source: Drug Development Technology)
Source: Drug Development Technology - October 20, 2009 Category: Pharmaceuticals Source Type: info

Peak Scientific Launches New TOC GeneratorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Peak Scientific, a pioneer in the development of laboratory gas generators, are proud to introduce the SC-TOC-A. This generator has been specifically designed to operate TOC-analysers, producing the required flow rates, purities and pressures to cater for TOC analysers. The SC-TOC-A has been tested extensively in the field by SWAN Environmental India, authorised Shimadzu Distributor for TOC. SWAN has approved this generator model to provide gas for both NPOC and TC-IC applications. The generator operates on the principle of catalytic oxidation to effectively remove hydrocarbons (as CH4) ... (Source: Drug Development Technology)
Source: Drug Development Technology - October 19, 2009 Category: Pharmaceuticals Source Type: info

Almac Expansion Expected to Create 500 Jobs Over the Next Five YearsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Almac, one of Northern Ireland's leading businesses, has secured planning permission for major expansion plans that could potentially see the company create over 500 jobs during the next five years. The global company, which provides integrated research, development and manufacturing services to pharmaceutical and biotech companies internationally, has experienced a substantial rate of growth at its Craigavon headquarters. Anticipating future growth requirements, Almac has acquired an adjacent 5.4ac site and will shortly embark on the first phase of development there. In 2008 staff numb... (Source: Drug Development Technology)
Source: Drug Development Technology - October 19, 2009 Category: Pharmaceuticals Source Type: info

Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry CollaborationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sygnature Chemical Services, a leading provider of premium medicinal chemistry and computational chemistry services to the global pharmaceutical industry, and Heptares Therapeutics, a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), have announced that they have entered into a contract chemistry collaboration in drug discovery. Under the terms of the agreement scientists from the two companies are working together to advance one of Heptares' internal high-value GPCR programmes. Sygnature is providing synthetic chemistry services to ... (Source: Drug Development Technology)
Source: Drug Development Technology - October 19, 2009 Category: Pharmaceuticals Source Type: info

New Coupling Agents from BachemEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The coupling reaction is the critical step in peptide synthesis. In particular, the solid-phase approach relies on rapid peptide bond formation and complete conversion with a minimum of concomitant side-reactions such as racemization. To meet these requirements a plethora of coupling (activation) reagents has been developed and employed since the early days of peptide synthesis. Coupling reagents (not forgetting the by-products formed during the coupling) have to fulfil additional requirements to be used in solid-phase synthesis, such as rapid dissolution and high solubility in DMF or NMP,... (Source: Drug Development Technology)
Source: Drug Development Technology - October 19, 2009 Category: Pharmaceuticals Source Type: info

NORMA Gains Gazelle Company StatusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NORMA has been appointed a gazelle company 2009 by Greens Analysis Institute in collaboration with the daily newspaper Borsen and Soliditet in Denmark. A gazelle company is the name given to a company that is among the most rapidly growing in Denmark. It is characterised by a positive growth over the last four fiscal years, and the turnover must be more than doubled over the entire period. ... (Source: Drug Development Technology)
Source: Drug Development Technology - October 15, 2009 Category: Pharmaceuticals Source Type: info

Qlucore's Magnus Fontes to Speak at Half-Day Workshop Looking at Innovation in the Life SciencesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Qlucore, a world leader in the development of bioinformatics software, has confirmed that Magnus Fontes is to co-host a workshop on the subject of innovation in the life sciences. The seminar, entitled 'Life Science Innovation Through Bioinformatics, Systems Biology and Visualisation', will be held on Wednesday 21 October at 9.30am, at the Technical University of Denmark in Lyngby. Magnus Fontes (PhD) is one of the founders of Qlucore, and also the head of the Centre for Mathematical Sciences at Lund University in Sweden. As part of the event he will be explaining how statistical inference... (Source: Drug Development Technology)
Source: Drug Development Technology - October 13, 2009 Category: Pharmaceuticals Source Type: info

Animascope Expands its Portfolio of Products for Disease Animal Models in Therapeutic Areas with Unmet Medical NeedsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Animascope is a provider of integrated contract research services in the field of discovery and pre-clinical, non-invasive biomedical imaging in vivo. Our staff has more than ten years of expertise in using X-Ray CT, nuclear imaging (PET / SPECT), magnetic resonance imaging (MRI), ultrasonography and optic imaging techniques to study healthy and disease animal models in various therapeutic fields, including oncology, bones and cardiology. Animascope also offers direct access to a range of established animal models, including subcutaneous and orthotopic cancer xenografts, models of metastasi... (Source: Drug Development Technology)
Source: Drug Development Technology - October 9, 2009 Category: Pharmaceuticals Source Type: info

Pipeline Biotech Offers Fast and Reliable PK Screening ProgrammesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rational drug discovery requires an early appraisal of all factors impacting on the likely drug-ability of a new chemical entity (NCE) in the subsequent preclinical, clinical and commercial phases of drug development. Since 39% of all NCEs fail on poor PK properties, pharmacokinetics has become an integrated part of the drug discovery screening process. Early in vivo PK studies in rodents provide unequivocal evidence of drug exposure. NCE selection and de-selection The emergence of combinatorial chemistry and the continued accumulation of a vast amount of NCEs have led to a need for f... (Source: Drug Development Technology)
Source: Drug Development Technology - October 7, 2009 Category: Pharmaceuticals Source Type: info

King's College London Chooses Qlucore Omics Explorer to Analyse Important Genetic DataEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Qlucore, a world leader in the development of bioinformatics software, has today announced that the Genomics Centre, a core research facility at King's College London, has chosen to use the Qlucore Omics Explorer for advanced data analysis on a wide range of research projects. As a core facility at King's College the Genomics Centre acts as a central resource for researchers, and also provides access to essential technology and genomics equipment for scientists based at King's College and beyond. King's College selected Qlucore's highly intuitive bioinformatics application following an in-d... (Source: Drug Development Technology)
Source: Drug Development Technology - October 7, 2009 Category: Pharmaceuticals Source Type: info

Animascope Collaborates with Speid & Associates on International Regulatory Affairs for a Faster Drug Development ProcessEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Animascope is a provider of integrated contract research services in the field of non-invasive biomedical imaging, for exploratory research. Animascope's staff has more than ten years of expertise in using X-ray CT, nuclear imaging (PET / SPECT), magnetic resonance imaging (MRI), ultrasonography and optic imaging techniques to study healthy and disease animal models in various therapeutic fields, including oncology, bones and cardiology. Pre-clinical imaging is a speedy and cost-effective approach to study the dynamic biodistribution, kinetics, efficacy and safety of therapeutics in vivo a... (Source: Drug Development Technology)
Source: Drug Development Technology - September 28, 2009 Category: Pharmaceuticals Source Type: info

Norwich Clinical Research to Feature on The Economic Report ShowEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The producers of The Economic Report are pleased to announce that Norwich Clinical Research Associates will be featured in an upcoming episode as part of the show's Medical Minutes Series which goes behind the scenes of drug and device development. This segment will air on the Fox Business Network and on CNN Headline News through regional cable operators and regional news networks in many of the top 100 markets nationwide.... (Source: Drug Development Technology)
Source: Drug Development Technology - September 24, 2009 Category: Pharmaceuticals Source Type: info

New Products from Bachem – Bioactive Molecules, Synthetic RANTES Peptides, LHRH Impurities and a Range of New Immunology ProductsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include a number of bioactive molecules, synthetic RANTES peptides, several LHRH impurities and a range of new immunology products. This latest release of 31 new products includes: RANTES (chemically synthesised) RANTES is a CC-chemokine that has the capability to inhibit certain strains of HIV-1, HIV-2 and simian immunodeficiency virus (SIV). RANTES (human) Met-RANTES (human) RANTES (3-68) (human) Adropin Adropin is... (Source: Drug Development Technology)
Source: Drug Development Technology - September 23, 2009 Category: Pharmaceuticals Source Type: info

Qlucore's New Omics Explorer 2.0 Software will Deliver Flexible and Creative Data Analysis for the Life Science and Biotech IndustryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Qlucore, a world leader in the development of bioinformatics software, has today unveiled the Qlucore Omics Explorer 2.0, a newly enhanced data analysis tool that has been developed for the life science and biotech industry. With its highly intuitive user interface, Qlucore Omics Explorer will allow researchers to shorten analysis time and add more creativity to research, thanks to the product's amazing speed and statistical analysis capabilities. As it provides users with immediate results, this latest version of Qlucore's software (previously known as Qlucore Gene Expression Explorer) wil... (Source: Drug Development Technology)
Source: Drug Development Technology - September 22, 2009 Category: Pharmaceuticals Source Type: info

Dr Reddy's Laboratories: Exhibitor at CPhI Worldwide Madrid 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
From 13-15 October 2009, Dr Reddy's Laboratories will be exhibiting at CPhI Worldwide 2009 in Madrid. Interested in our expertise in pharmaceutical development and manufacturing to provide custom manufacturing and development services for regulated starting materials (RSMs), intermediates, drug substance (API) and drug product (dosage form) needs with an exceptionally wide range of capabilities? Please contact us to make an appointment for CPhI Worldwide 2009. You can also visit our team at stand A30 in hall three during the exhibition. ... (Source: Drug Development Technology)
Source: Drug Development Technology - September 21, 2009 Category: Pharmaceuticals Source Type: info

Cerulean's FDA Expert on How to Avoid FDA and Courtroom TroublesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The AdvaMed 2009 conference in Washington, DC will host Cerulean's John Avellanet and former FDA prosecutor Nancy Singer, who will discuss how to ensure your internal company documents actually reflect your company’s commitment to product quality and patient safety, and the policies you’ll need to meet FDA requirements and reduce your risk in a lawsuit. Entitled 'Dangerous Documents: Avoiding Land Mines in Your FDA Records and Emails', this pre-conference executive workshop (free to all AdvaMed 2009 registered conference participants and their guests) will lay out why your firm – just like ... (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2009 Category: Pharmaceuticals Source Type: info

Dr Paul Clewlow Appointed Sygnature's Senior Vice-President for Business Development and Joins the Board of DirectorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nottingham, UK - Sygnature Chemical Services, a leading provider of medicinal chemistry, synthetic chemistry and chemical library services, is pleased to announce the appointment of Dr. Paul Clewlow as senior vice-president for business development, and as an executive member of the board of directors. Dr Simon Hirst, chief executive officer of Sygnature CS commented, "Paul is a great addition to Sygnature's senior management team. He has over 20 years' experience in business development through his involvement with pharmaceutical companies and CROs, and will be invaluable in helping u... (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2009 Category: Pharmaceuticals Source Type: info

Sygnature Chemical Services Announces New Appointments to the Board of DirectorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nottingham, UK - Sygnature Chemical Services is pleased to announce two new appointments to the board of directors: Dr Jonathan G Williams becomes director of operations following four years as principle research chemist at Sygnature CS. Jonathan is a highly-regarded chemist who also brings a wealth of commercial expertise to the board. Dr Paul J Clewlow joined Sygnature CS on 1st April 2009 as senior vice-president of business development. The rapid growth of Sygnature Chemical Services means that Paul's strategic expertise will be invaluable in helping to chart the future directi... (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2009 Category: Pharmaceuticals Source Type: info

Beth Harper to Facilitate Two International Patient Recruitment WorkshopsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
As the competition for enrolling patients in global clinical trials increases, so does the demand for enhancing the skill set to effectively plan and manage global recruitment programs. Beth Harper, president of Clinical Performance Partners, will facilitate several workshops in October for international audiences. As the keynote speaker at Poland's first conference on patient recruitment Harper will facilitate a discussion on 'Patient Recruitment and Retention Planning and Tactics - A Focus on Site Level Planning and Implementation'. The conference will be held in Warsaw, Poland, on 23 Oct... (Source: Drug Development Technology)
Source: Drug Development Technology - September 10, 2009 Category: Pharmaceuticals Source Type: info

Cool-Tech’s Evaporative Coolers Provide a Solution to Low Energy CoolingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The commitment to reduce carbon by central government is putting enormous pressure on everyone to find low energy alternatives. Even energy consultants who are being commissioned to provide solutions are at a loss to know how to produce such dramatic cuts once lighting and heating have been looked at. Cool-Tech’s EcoCooling evaporative coolers can now provide a solution to low energy cooling in more buildings than was ever considered three years ago. Evaporative cooling has now been developed and is up and running and saving money in areas where evaporative cooling was never even considered... (Source: Drug Development Technology)
Source: Drug Development Technology - September 8, 2009 Category: Pharmaceuticals Source Type: info

Evaporative Cooling – Turning Summer Temperatures into Spring TemperaturesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Anyone associated with facilities management in the public and commercial sector is facing an ever increasing challenge in the cooling of buildings. Electricity prices have made air conditioning a luxury that many cannot afford. The carbon impact of refrigeration-based systems cannot be lessened just by demanding a reduction of carbon. On top of this the latest building regulations, building design, occupancy and activity levels are actually calling for more cooling. Until recently the options for cooling buildings has been limited to either ventilation or air-conditioning. While ventila... (Source: Drug Development Technology)
Source: Drug Development Technology - September 8, 2009 Category: Pharmaceuticals Source Type: info

EcoCooling Provides Energy-Efficient Warehouse Storage Temperatures Below 25°CEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Many warehouses are now suffering the effects of heat, particularly in areas where mezzanine floors have been built. Also, many pharmaceutical products now need to be stored at temperatures below 25°C to comply with the requirements of the MHRA. Previously this temperature has only been properly achieved and maintained using expensive refrigeration-based air conditioning systems because simple ventilation systems are not able to match this standard. Cool-Tech can now offer a balanced, evaporatively-cooled ventilation scheme that can ensure full compliance. 18 EcoCoolers were installed ... (Source: Drug Development Technology)
Source: Drug Development Technology - September 8, 2009 Category: Pharmaceuticals Source Type: info

Evaporative Cooling - Cooling with Environmental ResponsibilityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Whether you work in an office, warehouse, factory, shop or showroom, most places require cooling in the summer months. Until recently the only cooling solution has been refrigeration-based air conditioning and this has been restricted to high yielding accommodation such as shops or offices. Furthermore, recent spiralling energy prices have put energy efficiency at the top of everybody’s 'to do' list and have raised questions about the sustainability of traditional air conditioning. Cool-Tech evaporative cooling can provide a simple, safe, low-cost alternative to air conditioning. Up to 3... (Source: Drug Development Technology)
Source: Drug Development Technology - September 8, 2009 Category: Pharmaceuticals Source Type: info

Syrris Enters Contract with Chemglass Life SciencesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Syrris, the leading chemistry automation product innovator, has signed an exclusive distribution agreement with Chemglass Life Sciences (Chemglass) in North America. As an experienced vendor of chemical reactor systems, Chemglass provides Syrris with the opportunity to work with their customer base to advance their existing reactor systems. Covering all Syrris batch reactor products, a network of 15 account managers will ensure excellent customer service is provided across the Syrris product portfolio. Syrris’s automated chemistry systems greatly complement the existing range of Chemglass r... (Source: Drug Development Technology)
Source: Drug Development Technology - September 4, 2009 Category: Pharmaceuticals Source Type: info

The Atlas Syringe Pump Offers Outstanding Versatility for Automated Reagent Dosing, Sampling or pH Control for ReactorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Atlas Syringe Pump, from leading chemistry automation product innovator Syrris, is a versatile volumetric dosing and/or sampling system consisting of two syringes, with up to six port valves. With the ability to provide two independent refilling flows, one continuous flow, reaction sampling, advanced pH control, as well as temperature dependent dosing, this easy-to-use system offers unrivalled flexibility. Furthermore, as each syringe can be used to aspirate from, or dispense to, the pump, the two syringes can be configured in a variety of different ways. With a wide flow rate range of ... (Source: Drug Development Technology)
Source: Drug Development Technology - September 4, 2009 Category: Pharmaceuticals Source Type: info

Fully-Automated, Easy-to-Control Microreactor Flow System - Africa Software Offers Unrivalled Flow Chemistry ControlEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Africa Microreactor Flow System from Syrris is flexible, easy-to-use, modular apparatus for faster, cleaner, safer flow chemistry. The innovative Africa software controls the whole system offering unattended synthesis, aqueous work-up and analysis. This allows R&D chemists to accelerate compound synthesis and reaction optimisation for drug discovery and process development. The Africa software automatically detects which modules are connected and allows the user to select a pre-defined fluidic set-up or create a new one with the user-friendly drag and drop interface. The user simpl... (Source: Drug Development Technology)
Source: Drug Development Technology - September 4, 2009 Category: Pharmaceuticals Source Type: info

Parallel Reactor Systems Offer Complete Process Control - Atlas Parallel Systems for Flexible Process OptimisationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Syrris has introduced the Atlas Parallel systems for complete process control. These multi-position reactor stations for up to eight jacketed reactors or round bottomed flasks offer full, independent control and logging of all reaction parameters. Controlled from a single PC, temperature, stirrer speed, pH, dosing, heat flow and turbidity can all be monitored simultaneously, making it ideal for process optimisation. A selection of Atlas Parallel systems are available, including the Parallel Atlas Lithium, which automates heating / cooling in round bottomed flasks or vials with magnetic sti... (Source: Drug Development Technology)
Source: Drug Development Technology - September 4, 2009 Category: Pharmaceuticals Source Type: info

Establishment of McClay Foundation Marks New Era for Northern IrelandEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Speaking today Sir Allen McClay, chairman of the Almac Group, formally announced the establishment of the McClay Foundation, a charitable trust that is one of the first of its kind in Northern Ireland. The Foundation aims to advance the use of diagnostic tools and drugs in the prevention, control and cure of disease; support and encourage research and innovation in the field of healthcare and allied technologies; increase capacity of all people and specifically those in the developing world to access the latest benefits in healthcare; and to generate and promote employment opportunities for th... (Source: Drug Development Technology)
Source: Drug Development Technology - September 4, 2009 Category: Pharmaceuticals Source Type: info

ARTES Becomes a Research Partner of the ChemBioTec Project Supported by Deutsche Stiftung UmweltEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ARTES Biotechnology has announced its collaboration with five other collaboration partners in a joint 28-month research programme that is granted by the national Deutsche Stiftung Umwelt within the ChemBioTec initiative. The Deutsche Bundesstiftung Umwelt DBU is one of Europe's largest foundations and promotes innovative and exemplary environmental projects. The funded project includes three academic partners and three biotech companies and is coordinated by Prof Dr Holger Zorn of the institute of food chemistry and food biotechnology at University Giessen. The interdisciplinary research... (Source: Drug Development Technology)
Source: Drug Development Technology - September 2, 2009 Category: Pharmaceuticals Source Type: info

Micom Laboratories Commissions a New 1,700ft³ (48m³) Climatic ChamberEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Micom Laboratories is pleased to announce its recent commissioning of a 1,700ft³ (48m³) Thermotron climatic chamber. At Micom, a laboratory specialized in cold chain and packaging testing in general, this chamber will be used to test multiple sets of boxes simultaneously for cold chain qualification, which will result in a more economical approach for cold chain qualification for the pharmaceutical industry. Micom’s new climatic chamber features a 7ft (2.1m) wide door and a loading ramp that also allows cold chain qualification of up to six shippers’ pallets simultaneously or three L... (Source: Drug Development Technology)
Source: Drug Development Technology - September 1, 2009 Category: Pharmaceuticals Source Type: info

Animascope to Sponsor the Scientific Meeting of the European Teratology Society, 6-10 September 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Animascope is pleased to announce that it is to sponsor the scientific meeting of the European Teratology Society (ETS). The meeting will be held in Arles, France, on 6-10 September 2009. Animascope's support of this meeting of high scientific value reflects the company's interest in the therapeutic field of reproductive medicine and reproductive toxicology. ... (Source: Drug Development Technology)
Source: Drug Development Technology - September 1, 2009 Category: Pharmaceuticals Source Type: info

Bachem - Your Partner for Opioid PeptidesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Several families of endogenous opioid peptides, the endorphins, enkephalins and dynorphins, have been identified in the mammalian central nervous system. The peptides of these families contain an N-terminal Tyr-Gly-Gly-Phe- sequence but are derived from different precursor proteins: proopiomelanocortin (POMC), proenkephalin (PENK) and prodynorphin (PDYN). Proteolytic processing of POMC results in the generation of ß-endorphin. Processing of PENK yields Met-enkephalin and Leu-enkephalin. Dynorphin A and B are derived from PDYN. An additional family of endogenous opioid peptides is repr... (Source: Drug Development Technology)
Source: Drug Development Technology - August 21, 2009 Category: Pharmaceuticals Source Type: info

Animascope Sponsors Major Drug Development Industry EventsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Animascope is dedicated to providing high-quality non-invasive biomedical imaging services, and regularly attends industry events in order to increase its presence in the sector and stay up to date with the latest developments in drug development technology. Animascope sponsored ESMI 2009, the European Molecular Imaging Meeting, which was held in May in Barcelona, Spain. In June, the company sponsored AFSTAL 2009 (Association Française des Sciences et Techniques de l'Animal de Laboratoire) which was held in Nantes, France, and also attended the partnering event for the Pharma Finance ... (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2009 Category: Pharmaceuticals Source Type: info

Exclusive Cooperation Between ARTES and the Ukrainian National Academy of SciencesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ARTES has announced that it has signed an exclusive marketing agreement with the Institute of Cell Biology of the National Academy of Science of Ukraine. The agreement is that the NAS technology based on the yeast organism Hansenula polymorpha is now exclusively marketed and licensed by ARTES Biotechnology worldwide, except in Ukraine. The technology licensed to ARTES covers new expression tools as well as production cell lines for various products, a.o. HepB antigen and Arginase. With this agreement ARTES expands its Hansenula technology platform and gains access to new processes and prod... (Source: Drug Development Technology)
Source: Drug Development Technology - August 6, 2009 Category: Pharmaceuticals Source Type: info

Sygnature Chemical Services Awarded £390,000 Grant for Business Investment by emdaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sygnature Chemical Services, a leading provider of medicinal chemistry and computational chemistry services to the global pharmaceutical industry, has been awarded a £390,000 Grant for Business Investment (GBI) award by the East Midlands Development Agency (emda) and the European Regional Development Fund (ERDF). Founded in 2004, Sygnature serves clients all over the world. The business has a team of 32 industry-experienced chemists based at its start-of-the-art facilities in BioCity Nottingham, one of Europe’s largest biosciences incubators. GBI is a discretionary scheme that provid... (Source: Drug Development Technology)
Source: Drug Development Technology - July 28, 2009 Category: Pharmaceuticals Source Type: info

c-LEcta Implements a Production Process for the Enzyme 4-LEss Acryl to Reduce Acrylamide in FoodEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Leipzig, Germany - Leipzig-based biotechnology company c-LEcta has established a pilot-scale production process for the enzyme 4-LEss Acryl, marking an important milestone on the path to market launch. The highly effective asparaginase prevents the formation of the potential carcinogen acrylamide during the processing of coffee, corn flakes, and other food products. The enzyme can be integrated into existing manufacturing processes during which acrylamide is formed, making it a valuable tool in the enhancement of food safety. Several years ago, large quantities of the potential cancer-... (Source: Drug Development Technology)
Source: Drug Development Technology - July 22, 2009 Category: Pharmaceuticals Source Type: info

Reknowned Oncologist Dr Martin Murphy Opens Almac Diagnostics' New HeadquartersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The headquarters of Almac Diagnostics, a division of the Almac Group, was officially opened today by renowned oncologist Dr Martin Murphy. Almac Diagnostics is based within the company’s headquarters in Craigavon, Northern Ireland, with additional facilities in Durham, North Carolina. Almac Chairman Sir Allen McClay has hailed today's opening as a "significant step forward for Almac". Alongside Dr Murphy, other guests included Upper Bann MLA David Simpson, Meta Crozier, the Mayor of Craigavon, managing director of Clients and Entrepreneurship Group for Invest NI, Ian Murphy, and other busin... (Source: Drug Development Technology)
Source: Drug Development Technology - July 20, 2009 Category: Pharmaceuticals Source Type: info

Bachem Presents 31 New ProductsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include several Aβ mutants, the FPRL2 ligand F2L, Phylloseptin-L2, a novel antidiabetogenic peptide and a range of new immunology products. Today's release of 31 new products includes: Amyloid β - protein fragments and related peptides Aβ mutants are valuable tools for studying amyloid β-protein neurotoxicity and the mechanisms of fibril formation. The Aβ (1-40) Dutch, Flemish, Arctic and Italian m... (Source: Drug Development Technology)
Source: Drug Development Technology - July 16, 2009 Category: Pharmaceuticals Source Type: info

Neurobehavioural Tests in Juvenile DogsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The number of clinical trials targeted towards paediatric patient populations is rapidly growing and so is the need for non-clinical safety data supporting these initiatives (NCEs and biologicals). NOTOX is finalising a 15-week repeated dose study using juvenile beagle dogs, ages ranging from six weeks to approximately six months, the latter translating to adulthood. This specific study adds, to the standard battery of investigations, a specific focus on neurobehavioural tests in juvenile beagle dogs. Using acepromazine and d-amphetamine as positive controls, neurobehavioral testing (su... (Source: Drug Development Technology)
Source: Drug Development Technology - July 8, 2009 Category: Pharmaceuticals Source Type: info